# Phosphate Binders > Phosphate binders for FMGE Pharmacology: calcium carbonate limits, sevelamer and lanthanum, iron-based binders, aluminium toxicity and with-meals rule. - Canonical URL: https://prepelephant.com/topics/fmge/pharmacology/phosphate-binders-fmge - Exam / course: FMGE · Subject: Pharmacology - Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team - First published: 2026-10-02 - Last updated: 2026-10-02 - How to cite: "Phosphate Binders", PrepElephant, https://prepelephant.com/topics/fmge/pharmacology/phosphate-binders-fmge ## Direct answer Phosphate binders work only when swallowed with the phosphate: taken during meals, calcium carbonate, calcium acetate, sevelamer, lanthanum and iron-based agents complex dietary phosphate in the gut lumen and carry it out unabsorbed. Dialysis-stage patients typically need one to two binder tablets per meal plus dietary restriction, titrated toward the roughly 3.5-5.5 mg/dL phosphate range used in practice. Calcium-based binders are the affordable Indian backbone: calcium carbonate is 40% elemental calcium with a 1500 mg daily cap on binder-derived elemental calcium, and calcium acetate binds more phosphate per milligram of calcium delivered. Non-calcium options matter when calcium is high or calcification is present: sevelamer carbonate lowers phosphate and LDL cholesterol but seizes levothyroxine and ciclosporin unless doses are spaced; ferric citrate and sucroferric oxyhydroxide bind iron-handedly with fewer tablets; aluminium hydroxide is restricted to brief courses because chronic use causes the aluminium toxicity triad of adynamic bone disease, dialysis encephalopathy and microcytic anaemia. ## What you must remember - **The timing rule:** binders are taken with meals and snacks containing phosphate — a binder swallowed between meals binds nothing; non-adherence tracks pill burden above all. - **Calcium carbonate:** cheap, 40% elemental calcium, acid-dependent (less effective with proton pump inhibitors); calcium acetate 25% elemental but binds more phosphate per unit calcium — widely stocked in Indian pharmacies. - **Calcium cap:** limit binder-derived elemental calcium to about 1500 mg daily; avoid calcium-based binders entirely with hypercalcaemia, arterial calcification or suppressed parathyroid hormone. - **Sevelamer carbonate 800 mg:** non-absorbed polymer, 1-2 tablets per meal titrated to phosphate; lowers LDL as collateral; reduces absorption of levothyroxine, ciclosporin and ciprofloxacin — separate dosing by hours. - **Lanthanum carbonate:** chewable with meals, effective with low pill count; gastrointestinal effects dominate. - **Iron-based binders:** ferric citrate (adds absorbed iron — watch ferritin) and sucroferric oxyhydroxide 500 mg once or twice daily — the fewest tablets in the class. - **Aluminium hydroxide:** effective but aluminium toxicity — adynamic bone disease, dialysis encephalopathy, microcytic anaemia — restricts it to short courses in refractory hyperphosphataemia. - **Whole-bone-package monitoring:** phosphate toward 3.5-5.5 mg/dL, corrected calcium, and intact parathyroid hormone held roughly two to nine times the assay upper limit on dialysis per KDIGO. ## A dialysis phosphate problem, unwound A 54-year-old on maintenance haemodialysis returns with phosphate 7.2 mg/dL despite calcium carbonate 1 g with each meal, corrected calcium 10.4 mg/dL, and intact parathyroid hormone within target. The audit proceeds in order: first the dietitian revisits — the phosphate load from dairy, nuts and processed foods with phosphate additives is invisible to patients; second the technique — is he chewing the tablets with the first bite, since post-meal swallowing wastes the dose; third the calcium ledger — he is already at 1200 mg elemental calcium, near the cap, with a calcium drifting high. The correct escalation is therefore non-calcium: sevelamer carbonate 800 mg, two tablets per meal, titrated against monthly phosphate — with levothyroxine moved to bedtime, four hours from any binder. Two months later the phosphate sits at 5.3 mg/dL and his LDL has fallen a bonus 18 mg/dL. Had his phosphate stayed stubborn at 7 with correct technique and sevelamer at full dose, a short aluminium-hydroxide course would be next — brief, monitored, abandoned the moment the target is met, because the aluminium syndromes were the price earlier dialysis generations paid. ## Where students slip The timing question is nearly free marks and still missed: binders go with food, and a stem describing perfect adherence "one hour after meals" describes a failed regimen. The second slip is calcium arithmetic — candidates forget that 1 g of calcium carbonate carries 400 mg of elemental calcium, and that the cap counts binder calcium alone; a hypercalcaemia stem on calcium carbonate points straight to the cap being breached. Third, interaction spacing: sevelamer with levothyroxine, ciclosporin or ciprofloxacin reduces their absorption — the answer is separation, not substitution. Finally, the aluminium triad — adynamic bone, encephalopathy, microcytic anaemia — appears as a set in options; a dialysis stem pairing chronic binder use with dementia or a microcytic picture expects aluminium. ## Frequently asked questions ### When are phosphate binders taken? With meals and phosphate-containing snacks — they complex dietary phosphate in the gut lumen, so timing with food is the entire mechanism of action. ### Why is elemental calcium from binders capped near 1500 mg daily? To limit iatrogenic hypercalcaemia and vascular calcification, especially when calcium-based binders are combined with vitamin D analogues in dialysis patients. ### What makes sevelamer different from calcium-based binders? It is a non-absorbed, calcium-free polymer that also lowers LDL cholesterol, but it binds co-administered drugs — levothyroxine, ciclosporin, ciprofloxacin — so dosing must be separated. ### Why is aluminium hydroxide no longer used long-term? Chronic aluminium exposure causes adynamic bone disease, dialysis encephalopathy and microcytic anaemia — it survives only as short-course rescue therapy for refractory hyperphosphataemia. ### What phosphate target guides titration in dialysis patients? Practice commonly titrates toward the roughly 3.5-5.5 mg/dL range, alongside corrected calcium and parathyroid hormone held about two to nine times the assay upper limit per KDIGO guidance.